Navigation Links
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Date:6/5/2011

PC have radiological evidence of bone metastases.  Once the cancer cells settle in the bone, they interfere with bone strength, often leading to bone pain, fracture and other complications that can significantly impair a man's health.  In fact, bone metastases are the main cause of disability and death in patients with CRPC.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

BAYER (reg'd) and the Bayer Cross (reg'd) are trademarks of Bayer.

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
2. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
5. Investigational Drug May Reduce Involuntary Movements in People With Parkinsons Disease
6. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
7. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
8. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
11. FDA Grants Orphan Drug Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... studies being presented at the,American Academy of Ophthalmology,s ... significant role to play in the diagnosis of ... quality care. In the first study, researchers ... diabetes being treated in multi-physician primary care,practice. The ...
... Synvista,Therapeutics, Inc. (AMEX: SYI ) announced today, ... Phase 2 clinical trial of alagebrium,(ALT-711), a novel ... (AGE)-cross-link breaker, in patients with chronic heart,failure (CHF). ... the efficacy and safety of alagebrium) is,designed to ...
Cached Medicine Technology:Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease 2Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease 3Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 2Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 3Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 4
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
(Date:4/17/2014)... less than 40 years away from a food shortage ... according to a top scientist at the U.S. Agency ... history, food production will be limited on a global ... said Dr. Fred Davies, senior science advisor for the ... as politically destabilizing by 2050 as energy issues are ...
(Date:4/17/2014)... work has transformed cancer care in Northern Ireland, has ... of Cancer Sciences., The Academy, which was launched in ... oncologists and cancer researchers which aims to reduce the ... Professor Johnston, whose leadership has seen cancer survival rates ... UK league table to near the top, has been ...
(Date:4/16/2014)... PHOENIX, Ariz. April 15, 2014 The Translational ... philanthropists at their annual Founders Dinner for their support ... The event took place March 28 in Scottsdale. , ... Catherine Ivy Foundation, received TGen,s John S. McCain Leadership ...
(Date:4/16/2014)... fertility treatments are the leading cause of increases in ... of premature birth, these results are not inevitable, concludes ... . The article identifies six changes in policy and ... and prematurity, including expanding insurance coverage for in vitro ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... , ... solution will support compliance and risk management centered on internal and financial controls. ... (PRWEB) May 21, ... solutions announced today that TPG Capital, a leading private investment firm, has selected the ...
... pressure monitoring (HBPM) program supported by the American Heart ... for patients with uncontrolled hypertension, according to a study. ... 18 to 85 years, and with Internet access were ... HBPM group. All patients had their blood pressure measured ...
... 2010 New and universally applicable definitions of malnutrition are ... These are the result of a major international collaboration that ... ASPEN. The importance of the work is emphasised by ... publication in Clinical Nutrition and the ASPEN journal ...
... But study finds that many don,t get counseling on when it,s ... People who don,t have a frank talk about sex with their ... to resume sexual activity, new research finds. , The study of ... the men were 30 percent more likely and women 40 percent ...
... ... leading information technology research and advisory company, recently released a case study that describes ... costs and months of internal development time by outsourcing its international card payment operations ... ...
... ... City, Utah and Clemson University, Clemson, South Carolina has signed a Memorandum of ... with Clemson University will develop existing and future products in the field of ... energy currently required by RO or Evaboration type processes. , ...
Cached Medicine News:Health News:TPG Capital Selects MetricStream GRC Platform to Boost its Internal Controls and Compliance 2Health News:Talk With Doctor Helps Heart Attack Patients Resume Sex 2Health News:Talk With Doctor Helps Heart Attack Patients Resume Sex 3Health News:Insightful Case Study Details How Electronic Payment Exchange Saved a Global Firm More Than $3 Million in PCI-Related Costs 2Health News:Water Enabled Technologies of Utah Signs MOU with Clemson University, South Carolina, for Water Desalination 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: